|
Match
|
Document |
Document Title |
|
|
5484608 |
Sustained-release drug delivery system
A sustained-release pharmaceutical composition comprising a highly soluble pharmaceutical agent, such as selegiline, in a pharmaceutical carrier comprising a hydrophilic polymer dispersed in a...
|
|
|
5484607 |
Extended release clonidine formulation
A method of providing a patient needing clonidine with an extended dosage of clonidine over a prolonged period of time. Such method involves administering to the patient an oral dosage unit...
|
|
|
5484600 |
Insecticidal composite timed released particle
A composite particle timed release pest control agent comprising a dense core particle, a floatation particle, a pesticide, and a composite forming adhesive. The density of the core particle adapts...
|
|
|
5484605 |
Agent for treating chronically inflammatory intestinal diseases
Chronic inflammatory intestinal diseases may be treated enterally pharmacologically active doses of said oxypurinol and or its alkali, alkaline earth, or ammonium salts.
|
|
|
5480654 |
Prolonged release dosage form of drug and method for producing the same
A prolonged release dosage form of drug made by coating a surface of an ungranulated medicinal particle with a water-insoluble material which is physiologically acceptable and does not dissolve in...
|
|
|
5480650 |
Programmed release tablets containing naproxen
Programmed release tablets, to be administered by oral route, containing from 500 to 1,200 mg of naproxen, made by mixtures of an immediate release granulate dry compacted containing from 5% to 28%...
|
|
|
5478572 |
Gepirone dosage form
Gepirone compositions having extended release properties contain a gepirone salt, a cellulosic polymer matrix and suitable quantities of pharmaceutical excipients. Dosage forms based thereon...
|
|
|
5476654 |
Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained
A process is described for preparing pharmaceutical compositions by co-grinding or dry mixing the active substance with cyclodextrins or with hydrophilic polymer materials which swell on contact...
|
|
|
5474985 |
Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
Methods and compositions for preventing or treating non-inflammatory elevated intraocular pressure associated with administered or endogenous steroids including administering to a mammalian...
|
|
|
5472710 |
Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture. Pharmaceutical preparation to be administered orally with controlled...
|
|
|
5464633 |
Pharmaceutical tablets releasing the active substance after a definite period of time
Pharmaceutical tablets releasing the active substance after a definite period of time, consisting of: a core containing the active substance and polymeric substances which swell and/or gel and/or...
|
|
|
5462747 |
Pharmaceutical sustained release matrix
A pharmaceutical sustained release homogeneous tablet or homogeneous tablet layer is formed by making a wet granulation using povidone (PVP) in alcohol as the granulating fluid which is mixed with...
|
|
|
5458888 |
Controlled release tablet formulation
The present invention provides a controlled release dosage form which may be made using a blend having an internal drug containing phase and an external phase which comprises a polyethylene glycol...
|
|
|
5453280 |
Production of pellets composed of an ephedrine derivative
A process for producing pellets which are markedly spherical and have a particle size in the range from 0.1 to 4 mm and an apparent density above 0.5 g/cm 3 , and which are composed of 90-100% by...
|
|
|
5451409 |
Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
The present invention is directed to a novel sustained release matrix and oral dosage form comprising a homogeneous matrix formed from a wet granulation containing an effective amount of a...
|
|
|
5445829 |
Extended release pharmaceutical formulations
An extended release pharmaceutical formulation adapted to approach zero order release of drug over a 12 to at least 24 hour period, comprised of a mixture of 0 to about 50% of an immediate release...
|
|
|
5439687 |
Dosage forms having zero-order dihydropyridine calcium antagonist release
Pharmaceutical dosage forms having a linear release rate of the 0 th order for the once-daily oral administration of 20-120 mg of nifedipine or of another calcium antagonist of the dihydropyridine...
|
|
|
5437872 |
Pharmaceutical compositions and a device for administering the same
A pharmaceutical tablet or lozenge is described, which comprises a non-absorbable pharmaceutically active agent, in combination with a tablet matrix, arranged for providing controlled and sustained...
|
|
|
5433951 |
Sustained release formulation containing captopril and method
A sustained release captopril formulation is provided which is in the form of a capsule containing captopril in a semi-solid matrix of at least one fatty acid glyceride and/or polyethylene glycol...
|
|
|
5430030 |
Nerve gas antidote
A prophylactic pretreatment for nerve gas and pesticide poisons which can be administered orally and which comprises the following agents, in combination: a. Pyridostigmine (pyridostigmine bromide)...
|
|
|
5429822 |
Biodegradable bursting release system
A biodegradable polymeric multiphasic release system of one or more biodegradable bursting units capable of delivering biologically active substances in a burst or pulse at predetermined times and...
|
|
|
5427798 |
Controlled sustained release tablets containing bupropion
A controlled sustained release tablet having at least one year shelf life and containing bupropion hydrochloride, hydroxypropyl methylcellulose and cysteine hydrochloride or glycine hydrochloride...
|
|
|
5419917 |
Controlled release hydrogel formulation
The invention is directed to a method for the modification of the rate of release of a drug from a hydrogel which is based on the use of an effective amount of a pharmaceutically acceptable...
|
|
|
5415864 |
Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting PH-dependent swelling
Colonic-targeted oral drug dosage forms composed of a drug confined within a crosslinked hydrogel that exhibits pH-dependent swelling and is composed of an ionizable comonomer such as acrylic acid,...
|
|
|
5415871 |
Therapeutic agents
A sustained release pharmaceutical formulation comprising xanthan gum, a pharmaceutically active ingredient for example, ibuprofen or flurbiprofen, and other optional excipients.
|
|
|
5413572 |
Osmotic dosage system for liquid drug delivery
An osmotic system is disclosed for delivering a beneficial agent formulation to an environment of use. The osmotic system comprises (a) an outside semipermeable wall, (b) a middle osmotically...
|
|
|
5409711 |
Pharmaceutical formulations
The taste of orally administered drugs is masked by coating the drug with a polymeric membrane which is soluble only at a pH of 5 or more. An acid substance is included in the formulation...
|
|
|
5409905 |
Cure for commond cold
Present invention is a non-toxic, flavor stable, pleasant tasting composition releasing Zn 2 + from compositions containing a highly ionizable zinc compound other than zinc gluconate that reduces...
|
|
|
5407686 |
Sustained release composition for oral administration of active ingredient
A sustained release tablet adapted to provide an initial immediate release of an active agent, a period of no release of the active agent, followed by a substantially constant, rate of release of...
|
|
|
5407682 |
Process for the preparation of azo-and /or disulfide polymer matrix drug delivery system for the site specific delivery of an active agent in the colon
Azo-and/or disulfide-containing polymers for use as drug delivery systems having site-specific release of the drug in the colon are obtained by polycondensation or polyaddition of an azo- and/or...
|
|
|
5399359 |
Controlled release oxybutynin formulations
A solid oral sustained release oxybutynin formulation includes a sustained release matrix including a gelling agent, an inert pharmaceutical diluent, and a cationic cross-linking agent.
|
|
|
5399360 |
Pharmaceutical compositions
A ketotifen pharmaceutical composition adapted for once-a-day oral administration e.g. based on a fat matrix.
|
|
|
5399358 |
Sustained release formulations for 24 hour release of metroprolol
A sustained release oral solid dosage form of metoprolol pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, a cationic...
|
|
|
5399362 |
Once-a-day metoprolol oral dosage form
A sustained release oral solid dosage form of metoprolol pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, a cationic...
|
|
|
5395628 |
Controlled release succinic acid microcapsules coated with aqueous acrylics
A controlled release pharmaceutical preparation comprising (a) a core containing a pharmaceutically active substance and an organic acid, and (b) a coating film formed on the surface of the core by...
|
|
|
5391377 |
Biphasic release formations for lipophilic acids
A pharmaceutical formulation comprises: (a) a C 12 -C 24 fatty acid, which may be saturated or mono- or poly-unsaturated, such as oleic or linoleic acid; and (b) a generally lipophilic...
|
|
|
5391378 |
Two-part medicinal tablet and method of manufacture
A medicinal tablet mechanical configuration is provided that permits prolonged absorption of a medicinal dosage through the gastro-intestinal tract of warm blooded animals. The tablet is formed...
|
|
|
5387421 |
Multi stage drug delivery system
A drug delivery system includes a first capsule half having an inner chamber for containing a drug therein. A plug is disposed in a passageway of the capsule half for plugging the opening thereof....
|
|
|
5378475 |
Sustained release drug delivery devices
A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained...
|
|
|
5378474 |
Sustained release pharmaceutical composition
The present invention relates to a pharmaceutical pellet composition having a core element including at least one highly soluble active ingredient and a core coating which is partially soluble at a...
|
|
|
5372998 |
Powdery material for preparing drug-coating solution
The present invention provides a powdery starting material for preparing a drug-coating solution, which has high safety as a drug component and is very rapidly dissolved in room temperature water...
|
|
|
5368862 |
Sustained release tablets containing alginate
Sustained release tablet comprising a microbially produced alginate-type polysaccharide and an active ingredient to be delivered in controlled fashion.
|
|
|
5368863 |
Long-term delivery device with early startup
The present invention is directed to an improvement in a delivery device, the device comprising a wall that surrounds an internal lumen or compartment which contains a beneficial agent or...
|
|
|
5364646 |
Oral pharmaceutical forms of pimobendan
Pharmaceutical forms of pimobendan for oral administration comprising citric acid, whereby a constant, satisfactory resorption is ensured even when there are major pH fluctuations in the...
|
|
|
5364620 |
Controlled absorption diltiazem formulation for once daily administration
A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane...
|
|
|
5364635 |
Solid drug form with a high verapamil content
A solid drug form containing not less than 90% by weight verapamil is produced by granulating at from 30° to 55° C. with a little water, drying and, where appropriate, conventional tableting or...
|
|
|
5358721 |
Antiviral therapy
A dosage form is disclosed for administering an antiviral drug to a patient in need of antiviral therapy.
|
|
|
5356467 |
Controlled release coatings derived from aqueous dispersions of zein
Stable aqueous dispersions of zein which may be used as controlled release coatings of pharmaceutical, animal, health, or food products in an inorganic solvent-free environment are disclosed, as...
|
|
|
5356635 |
Carbohydrate glass matrix for the sustained release of a therapeutic agent
A composition for the sustained release of a biologically active therapeutic agent wherein the matrix of the sustained release composition is composed of an amorphous carbohydrate glass matrix...
|
|
|
5344825 |
Methanediphosphonic acid formulations with ion exchangers
The invention relates to a novel advantageous oral dosage form for methanediphosphonates, especially the active ingredient disodium pamidronate. A preferred dosage form comprises: a)...
|